All In Biotech

Drug Trial Radar · NCT05021900

Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer

A Phase II, Multi-center, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Oct 13, 2021

Primary completion

Mar 31, 2023

Study completion Mar 31, 2023

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Aug 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.

Conditions

  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • Tenalisib 800mgDrug

    Tenalisib will be administered 800mg BID, orally

  • Tenalisib 1200mgDrug

    Tenalisib will be administered 1200mg BID, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Without Disease ProgressionTime frame: Approximately 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • High Technology Hospital Medcenter

    Batumi, Georgia

  • LLC Caucasus Medical Center

    Tbilisi, Georgia

  • Simon Khechinashvili University Hospital

    Tbilisi, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.